Search Results

1 - 3 of 3 items

  • Author: Sasho Dohcev x
Clear All Modify Search


An increasing tendency has recently emerged for the use of phytotherapeutic agents as alternative to commercial pharmacological agents for the treatment of benign prostate hyperplasia (BPH). The purpose of this study is to evaluate the effects of Serenoa repens alcohol extract treatment on BPH patients’ symptoms and major parameters during one-year follow-up.

The study was performed on 70 men aged 40 - 79 years (mean 60.58) with symptomatic BPH that were divided into a group of 40 patients treated with Serenoa repens extract (SRT) and a control group of 30 patients that received no treatment and were observed only. The following parameters were determined at the time of diagnosis (baseline), and after 6 and 12 months: prostate size, serum prostate-specific antigen (PSA) and uroflowmetry parameters including maximum flow rate (MFR), average flow rate (AFR) and post-voiding residual volume (PVRV). In addition, the relevant patient symptoms were evaluated using the International Prostate Symptom Score (IPSS) system.

The patients in the SRT group showed a statistically significant increment of the average MFR and AFR values and reduction of PV relative to the control group (p<0.05). The significant differences between the proportion of patients with prostate volume >40 ml in the SRE treated group vs. control group was observed (p<0.05). The mean IPSS score was highly significantly reduced in the SRT group (p<0.01).

The mild improvements of the urine flow, prostate size and IPSS score during 12 months treatment with the Serenoa repens extract indicate possible efficiency of this phytotherapeutic agent in patients with BPH.

Epithelioid Angiosarcoma of the Adrenal Gland. Report of a Case and Review of the Literature

Background: Primary mesenchymal neoplasms of the adrenal gland are rare, and a malignant one is an extraordinary finding. Angiosarcomas are uncommon neoplasms and account for less than 1% of sarcomas. Due to their rarity, they can easily be misdiagnosed, both by the clinician and the pathologist.

Case report: We present a case of 55 year old man with primary epitheloid angiosarcoma of the right adrenal gland and a review of the literature in an attempt to better define the clinical and pathological features of these neoplasms and their biologic potential. Immunohistochemical analyses were performed using endothelial cell markers (CD31, CD34 and Factor VIII). The analyses showed focal positivity of tumor cells, especially CD31 and weak focal positivity for tumor cells of Cytokeratin 18. The review of the literature showed 32 cases described up-to-date.

Conclusion: The present case emphasizes problems in differential diagnosis that arise from its epithelioid differentiation. We show review of the relevant literature which underlines the poor clinical outcome of adrenal angiosarcoma despite the adequate surgical treatment.


Introduction: Prostate carcinoma is the most frequent malign neoplasm among men with an ever-growing incidence rate. TMPRSS2-ERG fusion transcript leads to the androgen induction of ERG proto-oncogenes expression, representing a high presence of oncogenes alteration among prostate tumour cells.

Aim: The aim of this research was to detect and evaluate theTMPRSS2-ERG fuse transcript in the tissues of patients with prostate cancer, and establish a base of material of these samples for further genetic examination.

Materials and methods: The research was a prospective clinical study that involved and focused on random sampling of 101 patients (62 with prostate cancer-study group and 39 with benign changes in the prostate-control group). Real time PCR analysis for detection of the TMPRSS2-ERG fusion transcript in prostate tissue was performed and also data from the histopathology results of tissues were used, as well as data for the level of PSA (prostate-specific antigen) in blood.

Results: TMPRSS2-ERG fusion transcript was detected in 20 out of 62 (32.2%) patients with prostate carcinoma and among no patients with benign changes whatsoever. There were no significant differences between patients with/without detected TMPRSS2-ERG fusion related to Gleason score. Among 50%, in the study group this score was greater than 7 per/for Median IQR=7 (6-8). Significant difference was recognized, related to the average value of PSA in favour of significantly higher value of PSA in the study group with prostate cancer, but there was also no significant difference between samples with prostate cancer who were with/without detected TMPRSS2-ERG fusion transcript related to PSA level.

Discussion: The results from this research are in accordance with the values and results from analyses done in several research centres and oncological institutes.

Conclusion: The positive findings in small scale studies encourage the implementation of larger scale studies that will be enriched with results of genetic transcript in blood and urine and will define the positive diagnostic meaning of the TMPRSS-ERG fusion transcript.